Fabrizio Conti |
|
Professore Associato di Reumat...
|
Publications (94) View all
-
Article: Autoantibodies specific to a peptide of β2-glycoprotein I cross-react with TLR4, inducing a proinflammatory phenotype in endothelial cells and monocytes.
Tania Colasanti, Cristiano Alessandri, Antonella Capozzi, Maurizio Sorice, Federica Delunardo, Agostina Longo, Marina Pierdominici, Fabrizio Conti, Simona Truglia, Alessandra Siracusano, Guido Valesini, Elena Ortona, Paola Margutti[show abstract] [hide abstract]
ABSTRACT: β(2)-glycoprotein I (β(2)GPI) is the major antigenic target for antiphospholipid Abs. Anti-β(2)GPI Abs are a heterogeneous population of Igs targeting all domains of the molecule. Abs specific to β(2)GPI domain I are strongly associated with thrombosis and obstetric complications. In the present study, we sought to understand the possible pathogenic mechanism for this subset of anti-β(2)GPI Abs, investigating their potential cross-reactivity with other self-proteins involved in inflammatory or coagulant events. We compared the amino acid sequence of the β(2)GPI domain I with human proteins in a protein databank and identified a peptide sharing 88% identity with an epitope of human TLR4. A high percentage of patients with antiphospholipid syndrome (41%) and systemic lupus erythematosus (50%) presented serum IgG specific to this peptide. Anti-β(2)GPI peptide Abs binding the TLR4 were able to induce NF-κB activation in HEK293 cells that were stably transfected with the TLR4 gene. Anti-β(2)GPI peptide Abs induced activation of TLR4 and triggered interleukin-1 receptor-associated kinase phosphorylation and NF-κB translocation, promoting VCAM expression on endothelial cells and TNF-α release by monocytes. In conclusion, our observations suggest a novel pathogenic mechanism in the TLR4 stimulation by anti-β(2)GPI peptide Abs that links adaptive immune responses with innate immunity in antiphospholipid syndrome and systemic lupus erythematosus.Blood 08/2012; 120(16):3360-70. · 9.90 Impact Factor -
SourceAvailable from: Marina Pierdominici
Article: T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy.
Cristiano Alessandri, Cristiana Barbati, Davide Vacirca, Paola Piscopo, Annamaria Confaloni, Massimo Sanchez, Angela Maselli, Tania Colasanti, Fabrizio Conti, Simona Truglia, Andras Perl, Guido Valesini, Walter Malorni, Elena Ortona, Marina Pierdominici[show abstract] [hide abstract]
ABSTRACT: Autophagy, the cytoprotection mechanism that takes place under metabolic impairment, has been implicated in the pathogenesis of autoimmunity. Here, we investigated the spontaneous and induced autophagic behavior of T lymphocytes from patients with systemic lupus erythematosus (SLE) compared with that of T lymphocytes from healthy donors by measuring the autophagy marker microtubule-associated protein 1 light chain 3 (LC3)-II. No significant differences in spontaneous autophagy were found between T lymphocytes from patients with SLE and from healthy donors, apart from CD4(+) naive T cells from patients with SLE in which constitutively higher levels of autophagy (P<0.001) were detected. At variance, whereas treatment of T lymphocytes from healthy donors with serum IgG from patients with SLE resulted in a 2-fold increase in LC3-II levels (P<0.001), T lymphocytes from SLE patients were resistant to autophagic induction and also displayed an up-regulation of genes negatively regulating autophagy, e.g., α-synuclein. These findings could open new perspectives in the search for pathogenetic determinants of SLE progression and in the development of therapeutic strategies aimed to recover T-cell compartment homeostasis by restoring autophagic susceptibility.-Alessandri, C., Barbati, C., Vacirca, D., Piscopo, P., Confaloni, A., Sanchez, M., Maselli, A., Colasanti, T., Conti, F., Truglia, S., Perl, A., Valesini, G., Malorni, W., Ortona, E., Pierdominici, M. T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy.The FASEB Journal 07/2012; · 5.71 Impact Factor -
Article: Atypical presentation of anaplastic large T-cell lymphoma mimicking an articular relapse of rheumatoid arthritis in a patient treated with etanercept. A case report and literature review.
Federico De Angelis, Alice Di Rocco, Clara Minotti, Guido Valesini, Claudio Cartoni, Mara Riminucci, Fabrizio Conti, Erica Finolezzi, Daniele Armiento, Sara Grammatico, Laura Massaro, Angelo Fama, Gioia Colafigli, Catrine Viccarone, Robin Foà, Maurizio MartelliLeukemia research 06/2012; 36(9):e199-201. · 2.36 Impact Factor -
Article: Autoantibodies to estrogen receptor α interfere with T lymphocyte homeostasis and are associated with disease activity in systemic lupus erythematosus
Tania Colasanti, Angela Maselli, Fabrizio Conti, Massimo Sanchez, Cristiano Alessandri, Cristiana Barbati, Davide Vacirca, Antonella Tinari, Flavia Chiarotti, Antonello Giovannetti, Flavia Franconi, Guido Valesini, Walter Malorni, Marina Pierdominici, Elena Ortona[show abstract] [hide abstract]
ABSTRACT: Objective Estrogens influence many physiologic processes and are also implicated in the development or progression of numerous diseases, including autoimmune disorders. Aberrations of lymphocyte homeostasis that lead to the production of multiple pathogenic autoantibodies, including autoantibodies specific to estrogen receptor (ER), have been detected in the peripheral blood of patients with systemic lupus erythematosus (SLE). This study was undertaken to assess the presence of both anti-ERα and anti-ERβ antibodies in sera from patients with SLE, to analyze the effect of these antibodies on peripheral blood T lymphocyte homeostasis, and to evaluate their role as determinants of disease pathogenesis and progression.Methods Anti-ER antibody serum immunoreactivity was analyzed by enzyme-linked immunosorbent assay in samples from 86 patients with SLE and 95 healthy donors. Phenotypic and functional analyses were performed by flow cytometry and Western blotting.ResultsAnti-ERα antibodies were present in 45% of the patients with SLE, whereas anti-ERβ antibodies were undetectable. In healthy donors, anti-ERα antibodies induced cell activation and consequent apoptotic cell death in resting lymphocytes as well as proliferation of anti-CD3–stimulated T lymphocytes. A significant association between anti-ERα antibody values and clinical parameters, i.e., the SLE Disease Activity Index and arthritis, was found.Conclusion Our data suggest that anti-ERα autoantibodies interfere with T lymphocyte homeostasis and are significantly associated with lupus disease activity.Arthritis & Rheumatism 02/2012; 64(3):778 - 787. · 7.87 Impact Factor -
Article: Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study.
Fabrizio Conti, Fulvia Ceccarelli, Carlo Perricone, Francesca Miranda, Simona Truglia, Laura Massaro, Viviana Antonella Pacucci, Virginia Conti, Izabella Bartosiewicz, Francesca Romana Spinelli, Cristiano Alessandri, Guido Valesini[show abstract] [hide abstract]
ABSTRACT: Several indices have been proposed to assess disease activity in patients with Systemic Lupus Erythematosus (SLE). Recent studies have showed a prevalence of flare between 28-35.3%, persistently active disease (PAD) between 46%-52% and serologically active clinically quiescent (SACQ) disease ranging from 6 to 15%. Our goal was to evaluate the flare, PAD and SACQ rate incidence in a cohort of SLE patients over a 2-year follow-up. We evaluated 394 SLE patients. Flare was defined as an increase in SLEDAI-2K score of ≥4 from the previous visit; PAD was defined as a SLEDAI-2K score of ≥4, on >2 consecutive visits; SACQ was defined as at least a 2-year period without clinical activity and with persistent serologic activity. Among the 95 patients eligible for the analysis in 2009, 7 (7.3%) had ≥1 flare episode, whereas 9 (9.4%) had PAD. Similarly, among the 118 patients selected for the analysis in 2010, 6 (5%) had ≥1 flare episode, whereas 16 (13.5%) had PAD. Only 1/45 patient (2.2%) showed SACQ during the follow-up. We showed a low incidence of flare, PAD and SACQ in Italian SLE patients compared with previous studies which could be partly explained by ethnic differences.PLoS ONE 01/2012; 7(9):e45934. · 4.09 Impact Factor